Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results